Hubei Guangji Pharmaceutical Co Ltd (000952) - Net Assets
Based on the latest financial reports, Hubei Guangji Pharmaceutical Co Ltd (000952) has net assets worth CN¥593.68 Million CNY (≈ $86.87 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.29 Billion ≈ $335.75 Million USD) and total liabilities (CN¥1.70 Billion ≈ $248.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hubei Guangji Pharmaceutical Co Ltd (000952) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥593.68 Million |
| % of Total Assets | 25.88% |
| Annual Growth Rate | 5.46% |
| 5-Year Change | -56.79% |
| 10-Year Change | -4.9% |
| Growth Volatility | 29.64 |
Hubei Guangji Pharmaceutical Co Ltd - Net Assets Trend (1996–2025)
This chart illustrates how Hubei Guangji Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 000952 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hubei Guangji Pharmaceutical Co Ltd (1996–2025)
The table below shows the annual net assets of Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2025. For live valuation and market cap data, see Hubei Guangji Pharmaceutical Co Ltd (000952) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥626.85 Million ≈ $91.73 Million |
-41.75% |
| 2024-12-31 | CN¥1.08 Billion ≈ $157.48 Million |
-22.71% |
| 2023-12-31 | CN¥1.39 Billion ≈ $203.76 Million |
-6.66% |
| 2022-12-31 | CN¥1.49 Billion ≈ $218.30 Million |
+2.83% |
| 2021-12-31 | CN¥1.45 Billion ≈ $212.30 Million |
+6.23% |
| 2020-12-31 | CN¥1.37 Billion ≈ $199.84 Million |
+41.63% |
| 2019-12-31 | CN¥964.30 Million ≈ $141.11 Million |
+9.46% |
| 2018-12-31 | CN¥880.96 Million ≈ $128.91 Million |
+15.12% |
| 2017-12-31 | CN¥765.24 Million ≈ $111.98 Million |
+16.09% |
| 2016-12-31 | CN¥659.18 Million ≈ $96.46 Million |
+28.28% |
| 2015-12-31 | CN¥513.86 Million ≈ $75.19 Million |
+1.67% |
| 2014-12-31 | CN¥505.45 Million ≈ $73.96 Million |
-31.24% |
| 2013-12-31 | CN¥735.04 Million ≈ $107.56 Million |
-3.29% |
| 2012-12-31 | CN¥760.05 Million ≈ $111.22 Million |
-11.99% |
| 2011-12-31 | CN¥863.60 Million ≈ $126.37 Million |
+2.89% |
| 2010-12-31 | CN¥839.35 Million ≈ $122.82 Million |
+2.75% |
| 2009-12-31 | CN¥816.91 Million ≈ $119.54 Million |
+0.69% |
| 2008-12-31 | CN¥811.28 Million ≈ $118.72 Million |
+20.55% |
| 2007-12-31 | CN¥673.00 Million ≈ $98.48 Million |
+40.89% |
| 2006-12-31 | CN¥477.68 Million ≈ $69.90 Million |
-10.17% |
| 2005-12-31 | CN¥531.76 Million ≈ $77.81 Million |
+1.64% |
| 2004-12-31 | CN¥523.19 Million ≈ $76.56 Million |
+1.68% |
| 2003-12-31 | CN¥514.56 Million ≈ $75.30 Million |
+1.52% |
| 2002-12-31 | CN¥506.86 Million ≈ $74.17 Million |
+4.11% |
| 2001-12-31 | CN¥486.87 Million ≈ $71.24 Million |
+1.11% |
| 2000-12-31 | CN¥481.54 Million ≈ $70.46 Million |
+7.18% |
| 1999-12-31 | CN¥449.30 Million ≈ $65.75 Million |
+134.07% |
| 1998-12-31 | CN¥191.95 Million ≈ $28.09 Million |
+15.49% |
| 1997-12-31 | CN¥166.21 Million ≈ $24.32 Million |
+23.87% |
| 1996-12-31 | CN¥134.18 Million ≈ $19.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hubei Guangji Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 752.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥850.87 Million | 130.15% |
| Total Equity | CN¥653.77 Million | 100.00% |
Hubei Guangji Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hubei Guangji Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iljin HySolus Co Ltd
KO:271940
|
$302.44 Million |
|
E Split Corp Class A
TO:ENS
|
$302.46 Million |
|
Tatva Chintan Pharma Chem Limited
NSE:TATVA
|
$302.61 Million |
|
Leysen Jewellery Inc
SHG:603900
|
$302.62 Million |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$302.41 Million |
|
Palisade Bio Inc
NASDAQ:PALI
|
$302.38 Million |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class B
IS:KRDMB
|
$302.37 Million |
|
Korea Ratings Co. Ltd
KQ:034950
|
$302.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hubei Guangji Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,064,939,987 to 653,771,461, a change of -411,168,526 (-38.6%).
- Net loss of 404,494,390 reduced equity.
- Dividend payments of 50,946,079 reduced retained earnings.
- Other factors increased equity by 44,271,944.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-404.49 Million | -61.87% |
| Dividends Paid | CN¥50.95 Million | -7.79% |
| Other Changes | CN¥44.27 Million | +6.77% |
| Total Change | CN¥- | -38.61% |
Book Value vs Market Value Analysis
This analysis compares Hubei Guangji Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.42x to 3.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CN¥0.44 | CN¥5.96 | x |
| 1997-12-31 | CN¥0.55 | CN¥5.96 | x |
| 1998-12-31 | CN¥0.64 | CN¥5.96 | x |
| 1999-12-31 | CN¥1.49 | CN¥5.96 | x |
| 2000-12-31 | CN¥1.59 | CN¥5.96 | x |
| 2001-12-31 | CN¥1.61 | CN¥5.96 | x |
| 2002-12-31 | CN¥1.68 | CN¥5.96 | x |
| 2003-12-31 | CN¥1.70 | CN¥5.96 | x |
| 2004-12-31 | CN¥1.73 | CN¥5.96 | x |
| 2005-12-31 | CN¥1.76 | CN¥5.96 | x |
| 2006-12-31 | CN¥1.91 | CN¥5.96 | x |
| 2007-12-31 | CN¥2.21 | CN¥5.96 | x |
| 2008-12-31 | CN¥2.45 | CN¥5.96 | x |
| 2009-12-31 | CN¥2.61 | CN¥5.96 | x |
| 2010-12-31 | CN¥2.69 | CN¥5.96 | x |
| 2011-12-31 | CN¥2.67 | CN¥5.96 | x |
| 2012-12-31 | CN¥2.38 | CN¥5.96 | x |
| 2013-12-31 | CN¥2.46 | CN¥5.96 | x |
| 2014-12-31 | CN¥1.65 | CN¥5.96 | x |
| 2015-12-31 | CN¥1.69 | CN¥5.96 | x |
| 2016-12-31 | CN¥2.17 | CN¥5.96 | x |
| 2017-12-31 | CN¥2.51 | CN¥5.96 | x |
| 2018-12-31 | CN¥2.89 | CN¥5.96 | x |
| 2019-12-31 | CN¥3.14 | CN¥5.96 | x |
| 2020-12-31 | CN¥4.11 | CN¥5.96 | x |
| 2021-12-31 | CN¥4.25 | CN¥5.96 | x |
| 2022-12-31 | CN¥4.26 | CN¥5.96 | x |
| 2023-12-31 | CN¥3.85 | CN¥5.96 | x |
| 2024-12-31 | CN¥3.03 | CN¥5.96 | x |
| 2025-12-31 | CN¥1.89 | CN¥5.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hubei Guangji Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -64.83%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 3.54x
- Recent ROE (-61.87%) is below the historical average (1.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 12.98% | 15.16% | 0.47x | 1.83x | CN¥4.00 Million |
| 1997 | 19.27% | 22.68% | 0.42x | 2.00x | CN¥15.41 Million |
| 1998 | 13.41% | 15.96% | 0.43x | 1.97x | CN¥6.55 Million |
| 1999 | 6.99% | 17.80% | 0.27x | 1.44x | CN¥-13.51 Million |
| 2000 | 6.36% | 22.82% | 0.20x | 1.40x | CN¥-17.54 Million |
| 2001 | 5.05% | 13.21% | 0.24x | 1.56x | CN¥-24.10 Million |
| 2002 | 3.92% | 9.83% | 0.25x | 1.62x | CN¥-30.82 Million |
| 2003 | 1.50% | 3.77% | 0.24x | 1.68x | CN¥-43.76 Million |
| 2004 | 1.57% | 2.97% | 0.30x | 1.74x | CN¥-44.06 Million |
| 2005 | 1.61% | 2.48% | 0.39x | 1.66x | CN¥-44.57 Million |
| 2006 | 3.28% | 4.03% | 0.50x | 1.64x | CN¥-32.06 Million |
| 2007 | 27.55% | 23.12% | 0.80x | 1.50x | CN¥117.08 Million |
| 2008 | 11.91% | 15.58% | 0.47x | 1.61x | CN¥14.27 Million |
| 2009 | 5.43% | 9.59% | 0.34x | 1.65x | CN¥-36.24 Million |
| 2010 | 1.73% | 2.89% | 0.35x | 1.72x | CN¥-66.67 Million |
| 2011 | 0.59% | 1.07% | 0.30x | 1.85x | CN¥-76.76 Million |
| 2012 | -13.29% | -24.25% | 0.25x | 2.16x | CN¥-167.46 Million |
| 2013 | 0.34% | 0.50% | 0.31x | 2.16x | CN¥-69.27 Million |
| 2014 | -43.91% | -45.02% | 0.31x | 3.18x | CN¥-268.55 Million |
| 2015 | 4.08% | 3.73% | 0.35x | 3.16x | CN¥-30.30 Million |
| 2016 | 21.69% | 19.85% | 0.44x | 2.50x | CN¥76.44 Million |
| 2017 | 13.86% | 13.13% | 0.49x | 2.16x | CN¥29.29 Million |
| 2018 | 19.66% | 20.35% | 0.50x | 1.94x | CN¥84.40 Million |
| 2019 | 9.05% | 11.89% | 0.41x | 1.84x | CN¥-9.09 Million |
| 2020 | 5.44% | 10.85% | 0.35x | 1.44x | CN¥-62.66 Million |
| 2021 | 7.53% | 14.02% | 0.38x | 1.40x | CN¥-36.14 Million |
| 2022 | 3.35% | 6.31% | 0.32x | 1.64x | CN¥-99.93 Million |
| 2023 | -10.29% | -19.01% | 0.24x | 2.22x | CN¥-276.59 Million |
| 2024 | -27.73% | -46.23% | 0.23x | 2.62x | CN¥-401.79 Million |
| 2025 | -61.87% | -64.83% | 0.27x | 3.54x | CN¥-469.87 Million |
Industry Comparison
This section compares Hubei Guangji Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,420,170,475
- Average return on equity (ROE) among peers: 6.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hubei Guangji Pharmaceutical Co Ltd (000952) | CN¥593.68 Million | 12.98% | 2.86x | $302.41 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $3.21 Billion | 10.69% | 2.51x | $732.38 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $1.98 Billion | 1.15% | 0.48x | $308.51 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $-153.68 Million | 0.00% | 0.00x | $750.55 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.73 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $758.22 Million | 2.72% | 0.11x | $247.30 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $29.29 Billion | 5.81% | 0.36x | $8.36 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.65 Billion | -9.38% | 1.12x | $760.20 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $2.77 Billion | 13.80% | 0.31x | $1.32 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $127.61 Million | 29.20% | 0.15x | $1.63 Billion |
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.